Phenotype associated with APP duplication in five families

Brain

Volumn 129, Issue 11, 2006, Pages 2966-2976

  Cabrejo, Lucie ^a   Guyant Maréchal, Lucie ^a,b   Laquerrière, Annie ^c   Vercelletto, Martine ^d   De La Fournière, François ^e   Thomas Antérion, Catherine ^f   Verny, Christophe ^g   Letournel, Franck ^g   Pasquier, Florence ^h   Vital, Anne ^a   Checler, Frédéric ⁱ   Frebourg, Thierry ^a,b   Campion, Dominique ^b   Hannequin, Didier ^a,b,j  

^a Hospital and University Centre   (France)

^b INSERM   (France)

^c ROUEN UNIVERSITY HOSPITAL   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

^e Department of Geriatry   (France)

^f UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^g ANGERS UNIVERSITY HOSPITAL   (France)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^j NONE   (France)

more..

Author keywords

Alzheimer's disease; Amyloid angiopathy; APP duplication; Down's syndrome; Intracerebral haemorrhage

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; AMYLOID PRECURSOR PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; BRAIN HEMORRHAGE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL OBSERVATION; CONTROLLED STUDY; DEMENTIA; DENTATE GYRUS; DISEASE SEVERITY; DOWN SYNDROME; FAMILY; GENE DUPLICATION; GENE LOCUS; GENETIC ASSOCIATION; GRANULAR CELL; HIPPOCAMPUS; HUMAN; INCIDENCE; NERVE CELL; NEUROIMAGING; NEUROPATHOLOGY; NEUROPSYCHOLOGICAL TEST; ONSET AGE; PHENOTYPE; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; SEIZURE; VASCULAR AMYLOIDOSIS;

EID: 33749066060     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awl237     Document Type: Article

References (74)

1. Aoki M, Abe K, Oda N, Ikeda M, Tsuda T, Kanai M, et al. A presenilin-1 mutation in a Japanese family with Alzheimer's disease and distinctive abnormalities on cranial MRI. Neurology 1997; 48: 1118-20.
2. American Psychiatric Association. AP. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Washington, DC: APA; 1994.
3. Barelli H, Lebeau A, Vizzavona J, Delaere P, Chevallier N, Drouot C, et al. Characterization of new polyclonal antibodies specific for 40 and 42 amino acid-long amyloid beta peptides: their use to examine the cell biology of presenilins and the immunohistochemistry of sporadic Alzheimer's disease and cerebral amyloid angiopathy cases. Mol Med 1997; 3: 695-707.
4. Belza MG, Urich H. Cerebral amyloid angiopathy in Down's syndrome. Clin Neuropathol 1986; 5: 257-60.
5. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991; 82: 239-59.
6. Brooks WS, Kwok JB, Halliday GM, Godbolt AK, Rossor MN, Creasey H, et al. Hemorrhage is uncommon in new Alzheimer family with Flemish amyloid precursor protein mutation. Neurology 2004; 63: 1613-7.
7. Bugiani OA. Beta-related cerebral amyloid angiopathy. Neurol Sci 2004; 25 (Suppl 1): S1-S2.
8. Cardebat D, Doyon B, Puel M, Goulet P, Joanette Y. [Formal and semantic lexical evocation in normal subjects. Performance and dynamics of production as a function of sex, age and educational level]. Acta Neurol Belg 1990; 90: 207-17.
9. Cataldo AM, Petanceska S, Terio NB, Peterhoff CM, Durham R, Mercken M, et al. Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome. Neurobiol Aging 2004; 25: 1263-72.
10. Day SM, Strauss DJ, Shavelle RM, Reynolds RJ. Mortality and causes of death in persons with Down syndrome in California. Dev Med Child Neurol 2005; 47: 171-6.
11. De Jonghe C, Zehr C, Yager D, Prada CM, Younkin S, Hendriks L, et al. Flemish and Dutch mutations in amyloid beta precursor protein have different effects on amyloid beta secretion. Neurobiol Dis 1998; 5: 281-6.
12. Deloche G, Hannequin D. DO80. Paris: Edition du Centre de Psychologie Appliquée; 1997.
13. Donahue JE, Khurana JS, Adelman LS. Intracerebral hemorrhage in two patients with Down's syndrome and cerebral amyloid angiopathy. Acta Neuropathol (Berl) 1998; 95: 213-6.
14. Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a frontal assessment battery at bedside. Neurology 2000; 55: 1621-6.
15. Ellis RJ, Olichney JM, Thal LJ, Mirra SS, Morris JC, Beekly D, et al. Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, part XV. Neurology 1996; 46: 1592-6.
16. Fitzpatrick JL, Mize AL, Wade CB, Harris JA, Shapiro RA, Dorsa DM. Estrogen-mediated neuroprotection against beta-amyloid toxicity requires expression of estrogen receptor alpha or beta and activation of the MAPK pathway. J Neurochem 2002; 82: 674-82.
17. Folstein MF, Folstein SE, McHugh PR. 'Mini-Mental State'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
18. Fraser PE, Nguyen JT, Inouye H, Surewicz WK, Selkoe DJ, Podlisny MB, et al. Fibril formation by primate, rodent, and Dutch-hemorrhagic analogues of Alzheimer amyloid beta-protein. Biochemistry 1992; 31: 10716-23.
19. Glasson EJ, Sullivan SG, Hussain R, Petterson BA, Montgomery PD, Bittles AH. The changing survival profile of people with Down's syndrome: implications for genetic counselling. Clin Genet 2002; 62: 390-3.
20. Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, et al. Intraneuronal Abeta42 accumulation in human brain. Am J Pathol 2000; 156: 15-20.
21. Grabowski TJ, Cho HS, Vonsattel JP, Rebeck GW, Greenberg SM. Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy. Ann Neurol 2001; 49: 697-705.
22. Greenberg SM. Cerebral amyloid angiopathy: prospects for clinical diagnosis and treatment. Neurology 1998; 51: 690-4.
23. Greenberg SM, Shin Y, Grabowski TJ, Cooper GE, Rebeck GW, Iglesias S, et al. Hemorrhagic stroke associated with the Iowa amyloid precursor protein mutation. Neurology 2003; 60: 1020-2.
24. Griffin WS, Sheng JG, McKenzie JE, Royston MC, Gentleman SM, Brumback RA, et al. Life-long overexpression of S100beta in Down's syndrome: implications for Alzheimer pathogenesis. Neurobiol Aging 1998; 19: 401-5.
25. Grober E, Buschke H. Genuine memory deficits in dementia. Dev Neuropsychol 1987: 13-36.
26. Gyure KA, Durham R, Stewart WF, Smialek JE, Troncoso JC. Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome. Arch Pathol Lab Med 2001; 125: 489-92.
27. Hendriks L, van Duijn CM, Cras P, Cruts M, Van Hul W, van Harskamp F, et al. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene. Nat Genet 1992; 1: 218-21.
28. Herzig MC, Winkler DT, Burgermeister P, Pfeifer M, Kohler E, Schmidt SD, et al. Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat Neurosci 2004; 7: 954-60.
29. Iwatsubo T, Mann DM, Odaka A, Suzuki N, Ihara Y. Amyloid beta protein (A beta) deposition: A beta 42(43) precedes A beta 40 in Down syndrome. Ann Neurol 1995; 37: 294-9.
30. Jackson JF, North ER III, Thomas JG. Clinical diagnosis of Down's syndrome. Clin Genet 1976; 9: 483-7.
31. Jellinger KA. Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm 2002; 109: 813-36.
32. Lai F, Williams RS. A prospective study of Alzheimer disease in Down syndrome. Arch Neurol 1989; 46: 849-53.
33. Langui D, Girardot N, El Hachimi KH, Allinquant B, Blanchard V, Pradier L, et al. Subcellular topography of neuronal Abeta peptide in APPxPS1 transgenic mice. Am J Pathol 2004; 165: 1465-77.
34. Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ. Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis 1996; 3: 16-32.
35. Levy E, Carman MD, Fernandez-Madrid IJ, Power MD, Lieberburg I, van Duinen SG, et al. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 1990; 248: 1124-6.
36. Maat-Schieman M, Roos R, van Duinen S. Hereditary cerebral hemorrhage with amyloidosis-Dutch type. Neuropathology 2005; 25: 288-97.
37. Mann DM, Pickering-Brown SM, Takeuchi A, Iwatsubo T. Amyloid angiopathy and variability in amyloid beta deposition is determined by mutation position in presenilin-1-linked Alzheimer's disease. Am J Pathol 2001; 158: 2165-75.
38. McCarron MO, Nicoll JA. High frequency of apolipoprotein E epsilon 2 allele is specific for patients with cerebral amyloid angiopathy-related haemorrhage. Neurosci Lett 1998; 247: 45-8.
39. McDermott S, Moran R, Platt T, Wood H, Isaac T, Dasari S. Prevalence of epilepsy in adults with mental retardation and related disabilities in primary care. Am J Ment Retard 2005; 110: 48-56.
40. McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, et al. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 2005; 47: 191-9.
41. McVicker RW, Shanks OE, McClelland RJ. Prevalence and associated features of epilepsy in adults with Down's syndrome. Br J Psychiatry 1994; 164: 528-32.
42. Menendez M. Down syndrome, Alzheimer's disease and seizures. Brain Dev 2005; 27: 246-52.
43. Miravalle L, Tokuda T, Chiarle R, Giaccone G, Bugiani O, Tagliavini F, et al. Substitutions at codon 22 of Alzheimer's abeta peptide induce diverse conformational changes and apoptotic effects in human cerebral endothelial cells. J Biol Chem 2000; 275: 27110-6.
44. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41: 479-86.
45. Mori C, Spooner ET, Wisniewsk KE, Wisniewski TM, Yamaguch H, Saido TC, et al. Intraneuronal Abeta42 accumulation in Down syndrome brain. Amyloid 2002; 9: 88-102.
46. Natte R, Vinters HV, Maat-Schieman ML, Bornebroek M, Haan J, Roos RA, et al. Microvasculopathy is associated with the number of cerebrovascular lesions in hereditary cerebral hemorrhage with amyloidosis, Dutch type. Stroke 1998; 29: 1588-94.
47. Nicoll JA, Burnett C, Love S, Graham DI, Dewar D, Ironside JW, et al. High frequency of apolipoprotein E epsilon 2 allele in hemorrhage due to cerebral amyloid angiopathy. Ann Neurol 1997; 41: 716-21.
48. Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, et al. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci 2001; 4: 887-93.
49. Nochlin D, Bird TD, Nemens EJ, Ball MJ, Sumi SM. Amyloid angiopathy in a Volga German family with Alzheimer's disease and a presenilin-2 mutation (N141I). Ann Neurol 1998; 43: 131-5.
50. O'Riordan S, McMonagle P, Janssen JC, Fox NC, Farrell M, Collinge J, et al. Presenilin-1 mutation (E280G), spastic paraparesis, and cranial MRI white-matter abnormalities. Neurology 2002; 59: 1108-10.
51. Obici L, Demarchi A, de Rosa G, Bellotti V, Marciano S, Donadei S, et al. A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy. Ann Neurol 2005; 58: 639-44.
52. Oyama F, Cairns NJ, Shimada H, Oyama R, Titani K, Ihara Y. Down's syndrome: up-regulation of beta-amyloid protein precursor and tau mRNAs and their defective coordination. J Neurochem 1994; 62: 1062-6.
53. Panegyres PK, Kwok JB, Schofield PR, Blumbergs PC. A Western Australian kindred with Dutch cerebral amyloid angiopathy. J Neurol Sci 2005; 239: 75-80.
54. Pfeifer LA, White LR, Ross GW, Petrovitch H, Launer LJ. Cerebral amyloid angiopathy and cognitive function: the HAAS autopsy study. Neurology 2002; 58: 1629-34.
55. Revesz T, Holton JL, Lashley T, Plant G, Rostagno A, Ghiso J, et al. Sporadic and familial cerebral amyloid angiopathies. Brain Pathol 2002; 12: 343-57.
56. Rey A. Test de copie et de reproduction de mémoire de figures géométriques complexes. Paris: Edition du Centre de Psychologie Appliquée; 1970.
57. Roks G, Van Harskamp F, De Koning I, Cruts M, De Jonghe C, Kumar-Singh S, et al. Presentation of amyloidosis in carriers of the codon 692 mutation in the amyloid precursor protein gene (APP692). Brain 2000; 123: 2130-40.
58. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43: 250-60.
59. Rossi G, Giaccone G, Maletta R, Morbin M, Capobianco R, Mangieri M, et al. A family with Alzheimer disease and strokes associated with A713T mutation of the APP gene. Neurology 2004; 63: 910-2.
60. Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerriere A, Vital A, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 2006; 38: 24-6.
61. Schmidt R, Freidl W, Fazekas F, Reinhart B, Grieshofer P, Koch M, et al. The Mattis Dementia Rating Scale: normative data from 1,001 healthy volunteers. Neurology 1994; 44: 964-6.
62. Seo H, Isacson O. Abnormal APP, cholinergic and cognitive function in Ts65Dn Down's model mice. Exp Neurol 2005; 193: 469-80.
63. Strauss D, Shavelle R. Life expectancy of persons with chronic disabilities. J Insur Med 1998; 30: 96-108.
64. Takahashi RH, Milner TA, Li F, Nam EE, Edgar MA, Yamaguchi H, et al. Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol 2002; 161: 1869-79.
65. Van Buggenhout GJ, Trommelen JC, Schoenmaker A, De Bal C, Verbeek JJ, Smeets DF, et al. Down syndrome in a population of elderly mentally retarded patients: genetic-diagnostic survey and implications for medical care. Am J Med Genet 1999; 85: 376-84.
66. van den Boom R, Bornebroek M, Behloul F, van den Berg-Huysmans AA, Haan J, van Buchem MA. Microbleeds in hereditary cerebral hemorrhage with amyloidosis-Dutch type. Neurology 2005; 64: 1288-9.
67. Verkkoniemi A, Somer M, Rinne JO, Myllykangas L, Crook R, Hardy J, et al. Variant Alzheimer's disease with spastic paraparesis: clinical characterization. Neurology 2000; 54: 1103-9.
68. Visser FE, Aldenkamp AP, van Huffelen AC, Kuilman M, Overweg J, van Wijk J. Prospective study of the prevalence of Alzheimer-type dementia in institutionalized individuals with Down syndrome. Am J Ment Retard 1997; 101: 400-12.
69. Vonsattel JP, Myers RH, Hedley-Whyte ET, Ropper AH, Bird ED, Richardson EP Jr. Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study. Ann Neurol 1991; 30: 637-49.
70. Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjogren M, et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 2001; 32: 1318-22.
71. Walsh DM, Hartley DM, Condron MM, Selkoe DJ, Teplow DB. In vitro studies of amyloid beta-protein fibril assembly and toxicity provide clues to the aetiology of Flemish variant (Ala692→Gly) Alzheimer's disease. Biochem J 2001; 355: 869-77.
72. Watson DJ, Selkoe DJ, Teplow DB. Effects of the amyloid precursor protein Glu693→Gln 'Dutch' mutation on the production and stability of amyloid beta-protein. Biochem J 1999; 340: 703-9.
73. Wechsler D. Echelle clinique de mémoire. Forme 1. Paris: Edition du Centre de Psychologie Appliquée; 1970.
74. Yang Q, Rasmussen SA, Friedman JM. Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet 2002; 359: 1019-25.